At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.
- April 2026 — CDMO Opportunities And Threats Report
- Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness
- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- Why Your MES RFP Is Failing Before It Starts
- Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24
- Transendocardial Cell Delivery In Post‑Acute Myocardial Infarction
- Inside March Biosciences' CD5-Targeting CAR-T Approach
- Causal Mechanism And Effect Analysis (CMEA): FMEA's Simpler, Effective Alternative
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Maximizing MSC Yield And Quality: A Comparative Media Study
Maximize mesenchymal stem cell (MSC) expansion with a simplified culture process. New data demonstrates a high-performance, xeno-free media that eliminates the need for coatings or media exchanges.
-
Determining The Power Numbers For A Single-Use Mixing System
In designing a mixing process for scale-up, the power number is a critical parameter. Explore the determined power numbers for a single-use mixer at various mixing speeds and fill levels.
-
Optimize Your Approach To mAb Development
To meet the growing demand for mAbs and their variants, it is important to leverage opportunities for optimization as well as work with suppliers that have the resources to help your workflow thrive.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Improve Speed To Market By Mitigating Vial And Stopper Incompatibility
These studies indicate that with a properly assembled vial containment system, good CCI performance can be achieved with stoppers of a given elastomer, independent of configuration/size, or vial style.
-
Optimizing Safety Measures For rAAV Therapies
Explore common process-related impurities found in recombinant Adeno-Associated Virus (rAAV) vectors and the analytical testing methods used for these residuals.
-
Ensuring Supply Through Speed And Transparency
Through speed, transparency, and close collaboration, the pharmaceutical company was able to switch vendors seamlessly, maintaining virtually uninterrupted manufacturing operations.
-
Expansion Of Human Umbilical Cord-Derived MSCs
Discover how high-quality, multipotent stromal cells are efficiently produced for regenerative medicine. Learn about their impressive viability and critical marker expression for therapeutic uses.
-
Maintain Control Of Pharmaceutical Water Systems
Early TOC excursions often reveal hidden risks in water systems. Capturing samples at the moment of deviation helps teams confirm root causes faster, reduce uncertainty, and maintain control.
-
Aerobic Cultivation Of High-Oxygen-Demand Microorganisms
Discover how oxygen-enriched conditions and smart feeding strategies boost microbial growth. Prevent oxygen limitation, improve productivity, and maintain control for high-density bioprocessing success.
NEWSLETTER ARCHIVE
- 05.13.26 -- Manufacturing Moves Shaping Advanced Therapies
- 05.13.26 -- How MTP Is Transforming Pharma Production Lines
- 05.13.26 -- Rewriting Disease Biology Through LSD1 Inhibition
- 05.12.26 -- West Vantage: End-to-End Combination Product Solutions
- 05.12.26 -- STREAM Edition: Inside The Phased, Risk-Based Approach For CGT Materials
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections